PROTALIX BIOTHERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.15 USD | -2.54% |
|
0.00% | -35.39% |
| Mar. 14 | Transcript : Protalix BioTherapeutics, Inc., 2023 Earnings Call, Mar 14, 2024 | |
| Mar. 14 | Protalix BioTherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Evolution of the average Target Price on Protalix BioTherapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
5021f071baf8635ca8c05.tLwqkhBOZCfyOnwLU-0765xVcXDnwx-TLv-yG5YstM0.9epNpEApVEubYDhHIIZN3fAMCUCep3bRZ7v8XftF-5rR9B35IgovXoRrMQ~d85675e25f09936fd43e9cc1b60c6e94
Analysts' Consensus
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.15
USD
Average target price
13
USD
Spread / Average Target
+1,030.43%
High Price Target
16
USD
Spread / Highest target
+1,291.30%
Low Price Target
10
USD
Spread / Lowest Target
+769.57%
Consensus detail
Consensus revision (last 18 months)
Analysts covering Protalix BioTherapeutics, Inc.
| HC Wainwright |
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
- Stock Market
- Equities
- PLX Stock
- Consensus Protalix BioTherapeutics, Inc.
